22
8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TP1016L | Aviptadil Acetate | Vasoactive Intestinal Peptide acetate salt | RAAS , SARS-CoV |
Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmona... | |||
T80866 | VIP(Guinea pig) TFA | Vasoactive Intestinal Peptide, guinea pig TFA | |
Vasoactive Intestinal Peptide (VIP) Guinea pig TFA, a trophic and mitogenic factor, promotes growth in cultured whole embryos and acts as a gastrointestinal hormone, while also indicating potential neurotransmitter funct... | |||
TP1016 | Aviptadil | Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine) | |
Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction. | |||
TP1627L | Prepro VIP (111-122), human acetate | Prepro VIP (111-122), human acetate(123025-94-5 free base) | Others |
Prepro VIP (111-122), human acetate is a prepro-vasoactive intestinal polypeptide (VIP)–derived peptide, corresponding to residues 111-122. | |||
TP2103L | [D-p-Cl-Phe6,Leu17]-VIP acetate | Others | |
[D-p-Cl-Phe6,Leu17]-VIP acetate is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor (IC50 = 125.8 nM). | |||
TP1283L | VIP(6-28)(human, rat, porcine, bovine) acetate | Others | |
VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG). | |||
TP1283 | VIP(6-28)(human, rat, porcine, bovine) | ||
VIP(6-28)(human, rat, porcine, bovine) is a potent antagonist that effectively counteracts the effects of exogenous vasoactive intestinal peptide (VIP) on cyclic adenosine monophosphate (cAMP) signaling. | |||
TP2103 | [D-p-Cl-Phe6,Leu17]-VIP | ||
Selective vasoactive intestinal peptide (VIP) receptor antagonist (IC50 = 125.8 nM). Displays no activity on glucagon, secretin or GRF receptors. | |||
TP1635 | Prepro VIP (81-122), human | ||
Prepro VIP (81-122), human is a prepro-vasoactive intestinal polypeptide (VIP) derived peptide, corresponding to residues 81-122. | |||
TP1627 | Prepro VIP (111-122), human | ||
Prepro VIP (111-122), human is a prepro-vasoactive intestinal polypeptide (VIP)–derived peptide, corresponding to residues 111-122. | |||
T36635 | [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) | [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) | |
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) is an analog of GRF and a vasoactive intestinal peptide (VIP) antagonist. | |||
T83195 | Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) | ||
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP(1-7)-GRF(8-27) is a selective antagonist [1] for the vasoactive intestinal peptide 1 (VIP 1) receptor. | |||
T36428 | PACAP-related Peptide (human) (trifluoroacetate salt) | PACAP | |
PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adeny... | |||
TP1054 | PACAP (1-38), human, ovine, rat TFA | Pituitary Adenylate Cyclase Activating Polypeptide 38 (TFA) | |
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP... | |||
T80876 | Vasomera | ||
Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1]. | |||
T78003 | [D-p-Cl-Phe6,Leu17]-VIP TFA | ||
[D-p-Cl-Phe6,Leu17]-VIP TFA acts as a competitive and selective antagonist of the vasoactive intestinal peptide (VIP) receptor, exhibiting an IC50 of 125.8 nM. It shows no activity on glucagon, secretin, or growth hormon... | |||
T80069 | PACAP (6-27) (human, ovine, rat) | Pituitary adenylate cyclase-activating peptide (6-27) | |
PACAP (6-27) (human, ovine, rat) serves as an antagonist for the PACAP receptor, inhibiting the catecholamine response of the canine adrenal gland to vasoactive intestinal peptide (VIP). This compound holds promise for r... | |||
T82217 | Helospectin I | ||
Helospectin I, a neuropeptide belonging to the vasoactive intestinal peptide (VIP) family, exhibits vasodilatory and antihypertensive properties, effectively reducing blood pressure. It was initially isolated from the sa... | |||
T82216 | Helospectin II | ||
Helospectin II, a member of the vasoactive intestinal peptide (VIP) family, exhibits vasodilatory and antihypertensive properties that reduce blood pressure. This neuropeptide was initially isolated from the venom of the... | |||
T81571 | PACAP (1-38) free acid TFA | ||
PACAP (1-38) free acid TFA, an endogenous neuropeptide, effectively enhances antral motility and somatostatin secretion, while concurrently suppressing gastrin secretion and promoting the release of vasoactive intestinal... | |||
T78035 | [K15,R16,L27]VIP(1-7)/GRF(8-27) acetate | ||
[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is an acetate salt form of the peptide [K15,R16,L27]VIP(1-7)/GRF(8-27). This compound acts as a selective agonist for the VIP 1 receptor, displaying IC50 values of 2 nM for human... | |||
T81572 | PACAP (1-38) free acid | ||
PACAP (1-38) free acid, an endogenous neuropeptide, potently modulates gastrointestinal and neuroendocrine functions. It enhances antral motility, increases somatostatin secretion, and stimulates the release of vasoactiv... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03597 | VIP Protein, Human, Recombinant (His) | Human | HEK293 Cells |
VIP, or vasoactive intestinal peptide, is a neuropeptide of 28 amino acid residues that belongs to a glucagon/secretin superfamily, and it exerts its actions through three G-protein-coupled receptors (PAC1, VPAC1, and VP... | |||
TMPY-01120 | VPAC2 Protein, Human, Recombinant (mFc) | Human | HEK293 Cells |
VIP and PACAP receptor 2, or VIPR2 encodes the VPAC2 receptor, which binds both VIP and PACAP. VPAC2 is expressed throughout the central nervous system and the periphery. Mutations in the VIPR2 homolog in the mouse cause... | |||
TMPK-01505 | HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KD... | |||
TMPK-01492 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity i... | |||
TMPK-01501 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity i... | |||
TMPK-01491 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity i... | |||
TMPK-01506 | HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KD... | |||
TMPK-01504 | HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KD... |